45 CFR 164.512(i) (HIPAA Uses and Disclosures for Research Purposes)

The America Invents Act (AIA) — formally the Leahy-Smith America Invents Act, Public Law 112-29, signed into law on September 16, 2011 — is the most significant overhaul of U.S. patent law in over 60 years. Its central change, and the one most consequential for research institutions, is the switch from a first-to-invent to a first-inventor-to-file priority system, effective for any application with an effective filing date on or after March 16, 2013. This entry frames the AIA specifically around what changed operationally for a university technology transfer office (TTO): who wins priority, how prior art is defined, and — most practically — why filing timing relative to disclosure and publication became the decision that determines whether patent rights survive at all.

The core change: first-inventor-to-file replaces first-to-invent

Before the AIA, priority between two parties claiming the same invention was resolved by who actually invented it first — proven through conception and reduction-to-practice dates, corroborated by lab notebooks, and litigated in a USPTO interference proceeding when two applicants collided. Under the AIA’s first-inventor-to-file system, priority goes to whoever has the earliest effective filing date at the USPTO. Interference proceedings were replaced with narrower derivation proceedings, which only address whether a later filer derived the invention from, and filed without authorization of, an earlier inventor — they do not resolve a simple race between two independent inventors, because there is no such race left to resolve once a filing date controls. See CASRAI’s entry on pre-AIA 35 U.S.C. § 102 for the mechanics of the system the AIA replaced, and CASRAI’s guide to 35 U.S.C. § 102: Patent Novelty and Invention Disclosure Timing for how the current, post-AIA novelty statute actually operates.

Why this matters for TTOs: disclosure timing and publication-bar risk

The practical effect of first-inventor-to-file on a research institution is a compression of the decision window. Academic research runs on a publication culture — conference abstracts, preprints, poster sessions, thesis defenses, journal submissions — and every one of those events is a potential public disclosure. Under first-inventor-to-file, a TTO can no longer treat an early disclosure as merely a documentation problem to sort out later through an interference filing; if a competing party files first, the institution’s inventor generally loses priority regardless of who invented the technology first or how well-documented their lab notebook is. That reality reshapes invention-disclosure workflow around one operational rule: file (typically a low-cost provisional patent application, see also a worked example) before the earliest planned public disclosure, not after. TTOs that ask researchers to submit an invention disclosure using an invention disclosure form well ahead of a submission or presentation date — rather than treating the disclosure as a formality that can wait — are responding directly to this AIA-driven timing pressure. See CASRAI’s entry on prior art for how a disclosure actually becomes prior art against an institution’s own later filing.

The AIA’s grace period — and its real limits

The AIA did not eliminate all protection for an inventor’s own pre-filing disclosures. Under 35 U.S.C. § 102(b)(1) and (b)(2), a disclosure made by the inventor (or derived from the inventor) within the one year before the effective filing date is excepted from counting as prior art against that inventor’s own U.S. application — the AIA’s one-year grace period. Two limits matter operationally for a TTO. First, the grace period is a U.S.-only safety net: most major foreign patent offices, including the European Patent Office and China’s CNIPA, apply an absolute novelty standard with no general grace period for an inventor’s own prior disclosure, so a disclosure that falls comfortably inside the U.S. one-year window can already have destroyed patent rights abroad. Second, “disclosure” reaches further than a public talk or paper: in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. 123 (2019), the U.S. Supreme Court held that a commercial sale to a third party bound by a confidentiality agreement can still trigger the AIA’s on-sale bar under § 102(a)(1) — confidentiality of the transaction does not remove it from prior-art status. For institutions that keep foreign filing open as an option (commonly via a PCT application), the practical rule most TTOs apply is to file before any public disclosure and treat the U.S. grace period as a fallback, not a plan.

Other AIA changes a TTO should know

• Worldwide prior art. Pre-AIA law limited certain prior-art categories (public use, on-sale activity) to the United States. The AIA removed that geographic limitation — public use, sale, or availability anywhere in the world can now create prior art against a U.S. application.
• Post-grant review at the USPTO. The AIA created inter partes review (IPR) and post-grant review (PGR), administrative proceedings before the Patent Trial and Appeal Board that let a third party challenge an issued patent’s validity without full federal litigation — materially changing the risk calculus around licensing a patent that may later face a validity challenge.
• Micro-entity status and reduced fees. The AIA created a micro-entity fee category (in addition to the pre-existing small-entity category), which many university-owned applications qualify for, reducing certain USPTO filing and maintenance fees. See CASRAI’s breakdown of the cost of filing a patent for how entity status affects total spend.
• Prioritized examination and other procedural changes. The AIA also introduced a prioritized-examination track (Track One) for faster review at an additional fee, among other procedural adjustments to prosecution practice.

How this interacts with Bayh-Dole timing

The AIA’s filing-date pressure compounds with a separate, federally funded-research-specific clock. Under the Bayh-Dole Act and its implementing regulations, an institution must elect in writing whether to retain title to a federally funded invention within a set period after disclosing it to the funding agency (commonly tracked through iEdison) — and where a public disclosure has already started the § 102(b) one-year statutory clock running, that election window can be compressed. In practice, a single planned conference presentation or paper submission can simultaneously drive the patent-filing deadline and the institution’s internal Bayh-Dole election deadline, which is exactly why TTOs push invention disclosure earlier rather than later in the research timeline.

Related terms

• Pre-AIA 35 U.S.C. § 102 (the first-to-invent system the AIA replaced)
• 35 U.S.C. § 102: Patent Novelty and Invention Disclosure Timing
• Prior Art
• Provisional Patent Applications
• Bayh-Dole Act
• Invention Disclosure
• Tech transfer pillar page

Frequently Asked Questions

Does 45 CFR 164.512(i) let researchers use health information without patient authorization?

Yes. 164.512(i) is one of the provisions in 164.512 that lets a covered entity use or disclose PHI for research without the individual’s authorization and without giving the individual a chance to agree or object, provided the disclosure fits one of three specific pathways: an IRB or Privacy Board waiver, a review preparatory to research, or research on a decedent’s information.

What is a “review preparatory to research” under 164.512(i)(1)(ii)?

It is access to PHI that a researcher represents is sought solely to prepare a research protocol or for a similar preparatory purpose, such as assessing feasibility or estimating an eligible-patient population. The researcher must represent that no PHI will be removed from the covered entity and that the PHI is necessary for that purpose; it does not authorize recording identifiable data offsite.

Does 164.512(i) apply to research involving deceased patients?

Yes. A covered entity may use or disclose a deceased individual’s PHI for research if the researcher represents that the use is solely for research on decedents’ PHI, that the PHI is necessary for the research, and, if requested, provides documentation of death.

Is a limited data set the same as a 164.512(i) waiver?

No. Limited data sets — PHI stripped of the sixteen direct identifiers listed at 164.514(e)(2) and disclosed under a Data Use Agreement — are authorized under 45 CFR 164.514(e), a separate provision, not 164.512(i). See Data Use Agreement (DUA).

Are disclosures made under a 164.512(i) waiver exempt from the HIPAA accounting-of-disclosures requirement?

No. Unlike an authorized disclosure under 164.508, a disclosure made under a 164.512(i) waiver of authorization is not exempt from the accounting-of-disclosures right at 45 CFR 164.528. See HIPAA Accounting of Disclosures.

What are the three pathways for using PHI for research under 164.512(i)?

An IRB or Privacy Board approved waiver or alteration of authorization (164.512(i)(1)(i)), a review preparatory to research (164.512(i)(1)(ii)), or research on a decedent’s information (164.512(i)(1)(iii)). A disclosure must satisfy the documentation or representation requirements of one of these three — there is no general-purpose research exception covering activity outside them.